{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:41:22Z","timestamp":1759491682674,"version":"build-2065373602"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"2024 Zhejiang Provincial Medical and Health Science and Technology Program","award":["2024KY811"],"award-info":[{"award-number":["2024KY811"]}]},{"name":"2022 Zhejiang Provincial Medical and Health Science and Technology Program","award":["2022KY117"],"award-info":[{"award-number":["2022KY117"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The optimal timing of removal of implanted vascular access ports (PORTs) in cancer patients is unknown. This study aimed to explore the timing of PORT removal and the impact of PORT removal within 2 years in breast cancer patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This retrospective study included breast cancer patients who underwent PORT implantation at our Hospital between July 2012 and May 2022 and ultimately had their PORTs removed. QoL scores were assessed using the Karnofsky method. The primary endpoint was quality of life (QoL) (A: 80\u2013100 points, basically normal self-care ability; B: 60\u201379 points, mild dependence on self-care ability; C: &lt;60 points, moderate to severe dependence). The secondary endpoints included the proportion of unplanned PORT removal, secondary catheterization, medical costs, and complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study included 376 female patients with a median age of 52 (range, 22\u201372) years. The median PORT indwelling time was 464 (range, 16-2717) days. No significant differences were observed in the QoL scores between patients with PORT indwelling time\u2009\u2264\u20092 vs. &gt;2 years [A\/B\/C: 90.87%\/7.94%\/1.19% vs. 95.97%\/4.03%\/0, <jats:italic>P<\/jats:italic>\u2009=\u20090.185]. Patients with PORT indwelling time\u2009\u2264\u20092 years exhibited higher probabilities of unplanned port removal (16.76% vs. 3.99%, odds ratio\u2009=\u20092.42, <jats:italic>P<\/jats:italic>\u2009=\u20090.004), higher secondary catheterization (28.99% vs. 3.72%, odds ratio\u2009=\u20095.08, <jats:italic>P<\/jats:italic>\u2009=\u20090.004), and higher medical costs (24.57\u2009\u00b1\u200931.36 vs. 7.16\u2009\u00b1\u20091.19 CNY\/day, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) compared with patients with PORT indwelling time\u2009&gt;\u20092 years. There were no significant differences in the frequency of complications between groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.751). In the subgroup of patients with planned PORT removal, the \u2264\u20092-year group still showed significantly higher secondary catheterization rates (31.22% vs. 8.26%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) and daily costs (14.83 vs. 6.83 CNY\/day, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In patients with breast cancer who do not require regular intravenous administration, it may be recommended to consider removing the infusion port after 2 years to reduce the risks of secondary catheterization and reduce medical costs, unless irreversible adverse events affect the correct use of the PORT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12893-025-03173-4","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:02:19Z","timestamp":1759489339000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When to remove implantable vascular access ports? a retrospective analysis of 376 patients with breast cancer and implantable vascular access ports"],"prefix":"10.1186","volume":"25","author":[{"given":"Jun","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiren","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zifang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"3173_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3173_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3173_CR3","doi-asserted-by":"publisher","first-page":"E59","DOI":"10.1097\/NCQ.0000000000000708","volume":"38","author":"F Dang","year":"2023","unstructured":"Dang F, Zhai T, Ding N, Gao J, Li R, Li H, et al. Development and validation of a questionnaire to measure ICU nurses\u2019 knowledge, attitudes, and practices related to central line bloodstream infection practices. J Nurs Care Qual. 2023;38:E59\u201365.","journal-title":"J Nurs Care Qual"},{"key":"3173_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andre F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623\u201349.","journal-title":"Ann Oncol"},{"key":"3173_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101541","volume":"8","author":"SA Im","year":"2023","unstructured":"Im SA, Gennari A, Park YH, Kim JH, Jiang ZF, Gupta S, et al. Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer. ESMO Open. 2023;8: 101541.","journal-title":"ESMO Open"},{"key":"3173_CR6","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1093\/annonc\/mdz201","volume":"30","author":"S Loi","year":"2019","unstructured":"Loi S. The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. Ann Oncol. 2019;30:1183\u20134.","journal-title":"Ann Oncol"},{"key":"3173_CR7","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5306\/wjco.v7.i1.87","volume":"7","author":"FY Kreidieh","year":"2016","unstructured":"Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016;7:87\u201397.","journal-title":"World J Clin Oncol"},{"key":"3173_CR8","unstructured":"Kolikof J, Peterson K, Baker AM. Central venous catheter. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Katherine Peterson declares no relevant financial relationships with ineligible companies. Disclosure: Annalee Baker declares no relevant financial relationships with ineligible companies. 2023."},{"key":"3173_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1200\/JOP.2015.004796","volume":"11","author":"A Lipitz-Snyderman","year":"2015","unstructured":"Lipitz-Snyderman A, Ma Q, Pollack MF, Barron J, Elkin EB, Bach PB, et al. Complications associated with use of long-term central venous catheters among commercially insured women with breast cancer. J Oncol Pract. 2015;11:505\u201310.","journal-title":"J Oncol Pract"},{"key":"3173_CR10","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1200\/JCO.2013.53.3018","volume":"32","author":"A Lipitz-Snyderman","year":"2014","unstructured":"Lipitz-Snyderman A, Sepkowitz KA, Elkin EB, Pinheiro LC, Sima CS, Son CH, et al. Long-term central venous catheter use and risk of infection in older adults with cancer. J Clin Oncol. 2014;32:2351\u20136.","journal-title":"J Clin Oncol"},{"key":"3173_CR11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1136\/bmjspcare-2019-002106","volume":"11","author":"A Marin","year":"2021","unstructured":"Marin A, Bull L, Kinzie M, Andresen M. Central catheter-associated deep vein thrombosis in cancer: clinical course, prophylaxis, treatment. BMJ Support Palliat Care. 2021;11:371\u201380.","journal-title":"BMJ Support Palliat Care"},{"key":"3173_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1080\/17434440.2018.1500892","volume":"15","author":"S Raad","year":"2018","unstructured":"Raad S, Chaftari AM, Hachem RY, Shah P, Natividad E, Cleeland CS, et al. Removal and insertion of central venous catheters in cancer patients is associated with high symptom burden. Expert Rev Med Devices. 2018;15:591\u20136.","journal-title":"Expert Rev Med Devices"},{"key":"3173_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1097\/ALN.0b013e31826900cc","volume":"117","author":"MT Keegan","year":"2012","unstructured":"Keegan MT, Mueller JT. Removal of central venous catheters. Anesthesiology. 2012;117:917\u20138.","journal-title":"Anesthesiology"},{"key":"3173_CR14","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.12968\/bjon.2000.9.22.5417","volume":"9","author":"SR Drewett","year":"2000","unstructured":"Drewett SR. Central venous catheter removal: procedures and rationale. Br J Nurs. 2000;9:2304\u201315.","journal-title":"Br J Nurs"},{"key":"3173_CR15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.breast.2016.05.008","volume":"28","author":"Z Turfe","year":"2016","unstructured":"Turfe Z, Pettinga J, Leduc O, Leduc A, Komorowska-Timek E. Chemotherapy port related lymphedema after axillary lymph node dissection. Breast. 2016;28:145\u20137.","journal-title":"Breast"},{"key":"3173_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/01.RVI.0000082863.05622.2A","volume":"14","author":"RT Gandhi","year":"2003","unstructured":"Gandhi RT, Getrajdman GI, Brown KT, Gandras EJ, Covey AM, Brody LA, et al. Placement of subcutaneous chest wall ports ipsilateral to axillary lymph node dissection. J Vasc Interv Radiol. 2003;14:1063\u20135.","journal-title":"J Vasc Interv Radiol"},{"key":"3173_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","volume":"2","author":"CC Schag","year":"1984","unstructured":"Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol. 1984;2:187\u201393.","journal-title":"J Clin Oncol"},{"key":"3173_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on Disease-Free survival among patients with Early-Stage Triple-Negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA. 2021;325:50\u20138.","journal-title":"JAMA"},{"key":"3173_CR19","volume-title":"Breast cancer. Version 4.2025","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2025","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast cancer. Version 4.2025. Fort Washington: Nationall Comprehensive Cancer Network; 2025."},{"key":"3173_CR20","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF, Lang I, Ciruelos E, Bellet M, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436\u201346.","journal-title":"N Engl J Med"},{"key":"3173_CR21","doi-asserted-by":"publisher","first-page":"4864","DOI":"10.1200\/JCO.23.00557","volume":"41","author":"SY Baek","year":"2023","unstructured":"Baek SY, Noh WC, Ahn SH, Kim HA, Ryu JM, Kim SI, et al. Adding ovarian suppression to Tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial. J Clin Oncol. 2023;41:4864\u201371.","journal-title":"J Clin Oncol"},{"key":"3173_CR22","doi-asserted-by":"crossref","unstructured":"Practice Guidelines for Central Venous Access. 2020: An Updated Report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2020;132:8\u201343.","DOI":"10.1097\/ALN.0000000000002864"},{"issue":"Suppl 5","key":"3173_CR23","doi-asserted-by":"publisher","first-page":"v152","DOI":"10.1093\/annonc\/mdv296","volume":"26","author":"B Sousa","year":"2015","unstructured":"Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, et al. Central venous access in oncology: ESMO clinical practice guidelines. Ann Oncol. 2015;26(Suppl 5):v152\u201368.","journal-title":"Ann Oncol"},{"key":"3173_CR24","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1007\/s00330-010-2045-7","volume":"21","author":"UK Teichgraber","year":"2011","unstructured":"Teichgraber UK, Kausche S, Nagel SN, Gebauer B. Outcome analysis in 3,160 implantations of radiologically guided placements of totally implantable central venous port systems. Eur Radiol. 2011;21:1224\u201332.","journal-title":"Eur Radiol"},{"key":"3173_CR25","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s11845-020-02207-5","volume":"189","author":"ME Ince","year":"2020","unstructured":"Ince ME, Ozkan G, Ors N, Yildirim AK, Doganci S. Complications and pitfalls of central venous port catheters: experience with 782 patients with cancer. Ir J Med Sci. 2020;189:1371\u20137.","journal-title":"Ir J Med Sci"},{"key":"3173_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TCRM.S287544","volume":"17","author":"T Lichtenstein","year":"2021","unstructured":"Lichtenstein T, Mammadov K, Rau K, Grosse Hokamp N, Do TD, Maintz D, et al. Long-Term Follow-Up and clinical relevance of incidental findings of fibrin sheath and thrombosis on computed tomography scans of cancer patients with Port catheters. Ther Clin Risk Manag. 2021;17:111\u20138.","journal-title":"Ther Clin Risk Manag"},{"key":"3173_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.21873\/anticanres.14914","volume":"41","author":"S Furuhashi","year":"2021","unstructured":"Furuhashi S, Morita Y, Ida S, Muraki R, Kitajima R, Suzuki K, et al. Risk factors for totally implantable central venous access port-related infection in patients with malignancy. Anticancer Res. 2021;41:1547\u201353.","journal-title":"Anticancer Res"},{"key":"3173_CR28","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/annonc\/mdn701","volume":"20","author":"R Biffi","year":"2009","unstructured":"Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, et al. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. Ann Oncol. 2009;20:935\u201340.","journal-title":"Ann Oncol"},{"key":"3173_CR29","first-page":"CD004084","volume":"2012","author":"X Ge","year":"2012","unstructured":"Ge X, Cavallazzi R, Li C, Pan SM, Wang YW, Wang FL. Central venous access sites for the prevention of venous thrombosis, stenosis and infection. Cochrane Database Syst Rev. 2012;2012:CD004084.","journal-title":"Cochrane Database Syst Rev"},{"key":"3173_CR30","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMoa1500964","volume":"373","author":"JJ Parienti","year":"2015","unstructured":"Parienti JJ, Mongardon N, Megarbane B, Mira JP, Kalfon P, Gros A, et al. Intravascular complications of central venous catheterization by insertion site. N Engl J Med. 2015;373:1220\u20139.","journal-title":"N Engl J Med"},{"key":"3173_CR31","first-page":"103","volume":"5","author":"Y Li","year":"2022","unstructured":"Li Y, Guo J, Zhang Y, Kong J. Intravascular treatment for abnormal catheter positioning of port-a-cath system in the subclavian vein: a single-center study. J Interv Med. 2022;5:103\u201310.","journal-title":"J Interv Med"},{"key":"3173_CR32","doi-asserted-by":"publisher","first-page":"497","DOI":"10.21147\/j.issn.1000-9604.2020.04.07","volume":"32","author":"Z Yang","year":"2020","unstructured":"Yang Z, Li C, Liu W, Zheng Y, Zhu Z, Hua Z, et al. Complications and risk factors for complications of implanted subcutaneous ports for intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis. Chin J Cancer Res. 2020;32:497\u2013507.","journal-title":"Chin J Cancer Res"},{"key":"3173_CR33","doi-asserted-by":"publisher","first-page":"117955491984477","DOI":"10.1177\/1179554919844770","volume":"13","author":"AJ Skelton WPt, Franke","year":"2019","unstructured":"Skelton WPt, Franke AJ, Welniak S, Bosse RC, Ayoub F, Murphy M, et al. Investigation of complications following Port insertion in a cancer patient population: A retrospective analysis. Clin Med Insights Oncol. 2019;13:1179554919844770.","journal-title":"Clin Med Insights Oncol"},{"key":"3173_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012427","volume":"97","author":"XY Yu","year":"2018","unstructured":"Yu XY, Xu JL, Li D, Jiang ZF. Late complications of totally implantable venous access ports in patients with cancer: risk factors and related nursing strategies. Medicine (Baltimore). 2018;97: e12427.","journal-title":"Medicine (Baltimore)"},{"key":"3173_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/hae.14459","volume":"28","author":"D Swan","year":"2022","unstructured":"Swan D, Paran S, Nolan B. Port removal in patients receiving Emicizumab prophylaxis: a single centre experience and review of the literature. Haemophilia. 2022;28:42\u20135.","journal-title":"Haemophilia"},{"issue":"11","key":"3173_CR36","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/j.jpedsurg.2016.07.017","volume":"51","author":"TF Devji","year":"2016","unstructured":"Devji TF, Madenci AL, Carpino E, Leahy IC, Samnaliev M, Dearden JL, et al. Safety and cost-effectiveness of port removal outside of the operating room among pediatric patients. J Pediatr Surg. 2016;51(11):1891\u20135.","journal-title":"J Pediatr Surg"},{"key":"3173_CR37","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jvir.2019.10.012","volume":"31","author":"J Donnellan","year":"2020","unstructured":"Donnellan J, Smith CE, John P, Amaral JG. Is routine preprocedural bloodwork needed for elective central venous access device removals in children without bleeding dyscrasias?? J Vasc Interv Radiol. 2020;31:276\u201381. e1.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"3173_CR38","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1129729821991360","volume":"23","author":"K Wang","year":"2022","unstructured":"Wang K, Zhou Y, Huang N, Lu Z, Zhang X. Peripherally inserted central catheter versus totally implanted venous port for delivering medium- to long-term chemotherapy: a cost-effectiveness analysis based on propensity score matching. J Vasc Access. 2022;23(3):365\u201374.","journal-title":"J Vasc Access"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-025-03173-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-025-03173-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-025-03173-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T11:02:21Z","timestamp":1759489341000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcsurg.biomedcentral.com\/articles\/10.1186\/s12893-025-03173-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3173"],"URL":"https:\/\/doi.org\/10.1186\/s12893-025-03173-4","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"25 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Zhejiang Cancer Hospital (approval #IRB-2018-149). The requirement for individual consent was waived by the ethics committee of Zhejiang Cancer Hospital due to the retrospective nature of the study. This work has been carried out in accordance with the Declaration of Helsinki (2000) of the World Medical Association. All methods were performed in accordance with the relevant guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"420"}}